Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 19Terminated 5Unknown 3Withdrawn 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 8Sarcoma 1Myeloid 1Lymphoid 1Genitourinary 1

Conditions

Prostatic Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 87Specimen Handling 75pembrolizumab 74enzalutamide 57Radiosurgery 56Radiotherapy 51Docetaxel 50Androgen Antagonists 48Gemcitabine 42Nivolumab 40darolutamide 39Prednisone 35Abiraterone Acetate 33enfortumab vedotin 32Cisplatin 30Biopsy 30Carboplatin 29cabozantinib 28apalutamide 28Standard of Care 28abiraterone 26Pluvicto 26Blood Specimen Collection 25Radiation 23Leuprolide 23Ipilimumab 22X-Rays 18relugolix 17Triptorelin Pamoate 17Surveys and Questionnaires 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Mitoxantrone × Genitourinary × Clear all
NCT03258320 2026-01-12

A Randomised Trial of Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin (CDMS) Plus Surgery for Prostate Cancer Patients

Shanghai Jiao Tong University School of Medicine

Phase 2/3 Recruiting
300 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡